**SUPPLEMENTARY ONLINE CONTENT**

**Supplementary Figure S1.** Directed acyclic graph with level of income as exposure and major adverse clinical events as outcome

**Supplementary Figure S2.** Number of events, event rates, and hazard ratios (95% confidence intervals) between income and secondary clinical endpoints among **men** in study population I and II.

**Supplementary Figure S3.** Number of events, event rates, and hazard ratios (95% confidence intervals) between income and secondary clinical endpoints among **women** in study population I and II.

**Supplementary Figure S4.** Cumulative incidence on the association between **income** and secondary clinical outcomes adjusted for age and ethnicity.

**Supplementary Figure S5.** Cumulative incidence on the association between **education** and secondary clinical outcomes adjusted for age and ethnicity.

**Supplementary Figure S6.** Number of events, event rates, and hazard ratios (95% confidence intervals) on the association between income and non-persistence to **statins** as well as the mediating effect on the association between income and risk of MACE among **men**, adjusted for age and ethnicity.

**Supplementary Figure S7.** Number of events, event rates, and hazard ratios (95% confidence intervals) on the association between income and non-persistence to **antiplatelets** as well as the mediating effect on the association between income and risk of MACE among **men**, adjusted for age and ethnicity.

**Supplementary Table S1.** ATC-, ICD-10-, and procedure codes

**Supplementary Table S2.** Baseline characteristics of study population II (**education** as exposure) stratified by sex.

**Supplementary Table S3.** Events, event rates (95% CI), and hazard ratios (95% CI) for the association between **income** and risk of non-persistence to medication and clinical events using none or 30-days window of initiation of medication

**Supplementary Table S4.** Events, event rates (95% CI), and hazard ratios (95% CI) for the association between **education** and risk of non-persistence to medication and clinical events using none or 30-days window of initiation of medication

**Supplementary Figure S1.** Directed acyclic graph with major adverse cardiovascular events (MACE) as outcome




Minimal adjustment after adjusting for initiation: education, civil status, ethnicity, age, comorbidities somatic, comorbidities psychiatric, sex

**Supplementary Figure S2.** Number of events, event rates, and hazard ratios (95% confidence intervals) between income and secondary clinical endpoints among **men** in study population I and II.



**Supplementary Figure S3.** Number of events, event rates, and hazard ratios (95% confidence intervals) between income and secondary clinical endpoints among **women** in study population I and II.



**Supplementary Figure S4.** Cumulative incidence on the association between income and secondary outcomes adjusted for age and ethnicity.

Study population I (income as exposure)



**Supplementary Figure S5.** Cumulative incidence on the association between education and secondary outcomes adjusted for age and ethnicity.



**Supplementary Figure S6.** Number of events, event rates, and hazard ratios (95% confidence intervals) on the association between income and non-persistence to **statins** as well as the mediating effect on the association between income and risk of MACE among **men**, adjusted for age and ethnicity

**Non-persistence to statins**

| | Unadjusted | | | Model I | | |
|---|---|---|---|---|---|---|
| | No. of events | Event rate per 100,000 pr. yrs. | HR | No. of events | Event rate per 100,000 pr. yrs. | HR |
| **Study population I (income as exposure)** | | | | | | |
| Low | 2,381 | 20.7 (19.9-21.6) | 1 (reference) | 2,651 | 21.5 (20.5-22.5) | 1 (reference) |
| Middle | 2,321 | 16.1 (15.4-16.7) | 0.77 (0.73-0.82) | 2,397 | 16.1 (15.5-16.8) | 0.75 (0.71-0.79) |
| High | 2,227 | 13.8 (13.2-14.4) | 0.66 (0.62-0.69) | 2,312 | 14.4 (13.7-15.1) | 0.65 (0.61-0.70) |
| **Study population II (education as exposure)** | | | | | | |
| Low | 2,358 | 17.1 (16.4-17.8) | 1 (reference) | 2,365 | 16.9 (16.2-17.6) | 1 (reference) |
| Middle | 3,261 | 16.1 (15.6-16.7) | 0.94 (0.90-1.00) | 3,260 | 16.2 (15.7-16.8) | 0.96 (0.91-1.01) |
| High | 1,310 | 16.2 (15.4-17.1) | 0.94 (0.88-1.01) | 1,305 | 16.2 (15.3-17.1) | 0.95 (0.89-1.02) |




**The mediating effect of non-persistence to statins among men**

| Level of income | Total effect (HR, 95% CI) | Direct effect (HR, 95% CI) | Indirect effect (HR, 95% CI) | Mediated proportion (%) |
|---|---|---|---|---|
| Low | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| Middle | 0.78 (0.75-0.81) | 0.82 (0.79-0.85) | 0.96 (0.95-0.96) | 18.1 (15.4-20.8) |
| High | 0.67 (0.64-0.70) | 0.72 (0.69-0.75) | 0.94 (0.93-0.94) | 16.3 (14.2-18.3) |

**Supplementary Figure S7.** Number of events, event rates, and hazard ratios (95% confidence intervals) on the association between income and non-persistence to **antiplatelets** as well as the mediating effect on the association between income and risk of MACE among **men**, adjusted for age and ethnicity.

**Non-persistence to antiplatelets**

| | Unadjusted | | | Model I | | |
|---|---|---|---|---|---|---|
| | No. of events | Event rate per 100,000 pr. yrs. | HR | No. of events | Event rate per 100,000 pr. yrs. | HR |
| **Study population I (income as exposure)** | | | | | | |
| Low | 2,183 | 18.3 (17.6-19.1) | 1 (reference) | 2,356 | 18.1 (17.3-19.0) | 1 (reference) |
| Middle | 2,222 | 14.8 (14.2-15.4) | 0.81 (0.76-0.86) | 2,282 | 14.8 (14.2-15.4) | 0.82 (0.77-0.87) |
| High | 2,311 | 14.0 (13.4-14.5) | 0.76 (0.71-0.80) | 2,605 | 16.0 (15.3-16.8) | 0.87 (0.81-0.93) |
| **Study population II (education as exposure)** | | | | | | |
| Low | 2,253 | 15.8 (15.2-16.5) | 1 (reference) | 2,228 | 15.3 (14.7-16.0) | 1 (reference) |
| Middle | 3,056 | 14.6 (14.0-15.1) | 0.92 (0.87-0.97) | 3,109 | 14.9 (14.4-15.5) | 0.98 (0.92-1.03) |
| High | 1,407 | 17.1 (16.2-18.0) | 1.07 (1.01-1.15) | 1,413 | 17.2 (16.3-18.1) | 1.12 (1.05-1.20) |




**The mediating effect of non-persistence to antiplatelets among men**

| Level of income | Total effect (HR, 95% CI) | Direct effect (HR, 95% CI) | Indirect effect (HR, 95% CI) | Mediated proportion (%) |
|---|---|---|---|---|
| Low | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| Middle | 0.78 (0.75-0.81) | 0.81 (0.77-0.84) | 0.97 (0.97-0.97) | 11.8 (10.1-13.6) |
| High | 0.67 (0.64-0.70) | 0.69 (0.66-0.72) | 0.97 (0.97-0.98) | 6.5 (5.7-7.4) |

**Supplementary Table S1.** ICD-10 codes, ATC-codes, and procedure codes used in present study

| **Main diagnosis** | **ICD-10 codes** | |
|---|---|---|
| Acute coronary syndrome | I200, I21, I24 | |
| **Outcome/diagnosis** | | |
| Cardiac death | I20-I25 | |
| Acute cardiac readmission: | | |
| Acute myocardial infarction | I21-I22 | |
| Stroke | I60-I64 | |
| Cardiac arrest | I46 | |
| Chronic heart failure | I11.0, I42.0, I42.6, I42.8, I50 | |
| Ventricular tachycardia or fibrillation | II49.0 | |
| **Mediator** | **ATC code** | |
| Antiplatelets | B01AC04, B01AC06, B01AC22, B01AC24 | |
| Statins | C10AA | |
| **Procedures** | **Procedure code** | |
| Percutaneous coronary intervention | KFNG00, KFNG01, KFNG02, KFNG05, KFNG10, KFNG12, KFNG20, KFNG22, KFNG30, KFNG40, KFNG96, KZFX01 | |
| **Charlson Comorbidity Index** | **Assigned weighting** | **ICD-10 Code** |
| AMI | 1 | I21, I22, I23, I410 |
| CHF | 1 | I50, I110, I130, I132 |
| Peripheral vascular disease | 1 | I70, I71, I72, I73, I74, I77 |
| Cerebral vascular accident | 1 | G45, G46, I60, I61, I62, I63, I64, I65, I66, I67, I68, I69 |
| Dementia | 1 | F00, F01, F02, F03, F051, G30 |
| Pulmonary disease | 1 | J40, J41, J42, J43, J44, J45, J46, J47, J60, J61, J62, J63, J64, J65, J66, J,67, J684 J701, J703. J841, J920, J961, J982, J983 |
| Connective tissue disorder | 1 | M05, M06, M08, M09, M30, M31, M32, M33, M34, M35, M36, D86 |
| Peptic ulcer | 1 | K221, K25, K26, K27, K28, |
| Mild liver disease | 1 | B18, K700, K701, K702, K703, K709, K71, K13, K74, K760 |
| Diabetes without complications | 1 | E100, E101, E109, E110, E111, E119, |
| Diabetes with chronic complications | 2 | E102, E103, E104, E105, E107, E108, E112, E113, E114, E115, E117, E118 |
| Hemiplegia | 2 | G81, G82 |
| Renal disease | 2 | I12, I13, N00, N01, N02, N03, N04, N05, N07, N11, N14, N17, N18, N19, Q61 |
| Any tumour | 2 | C00, C01, C02, C03, C04, C05, C06, C07, C08, C09, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C23, C24, C25, C26, C27, C28, C29, C30, C31, C32, C33, C34, C35, C36, C37, C38, C39, C40, C41, C42, C43, C44, C45, C46, C47, C48, C49, C50, C51, C52, C53, C54, C55, C56, C57, C58, C59, C60, C61, C62, C63, C64, C65, C66, C67, C68, C69, C70, C71, C72, C73, C74, C75 |
| Leukaemia | 2 | C91, C92, C93, C94, C95 |
| Lymphoma | 2 | C81, C82, C83, C84, C85, C88, C90, C96 |
| Moderate or severe liver disease | 3 | B150, B160, B162, B190, K704, K72, K766, I85, |
| Metastatic solid tumour | 6 | C76, C77, C78, C79, C80 |
| Aids/HIV | 6 | B21, B22, B23, B24 |
| **Psychiatric comorbidity** | **ICD-10 codes** | **ATC-codes** |
| Depression, Anxiety, OCD | F32, F33<br>F40-F42 | N06A excluding N06AX12 and N06AX21<br>N05B and N05C excluding N05CH01 |

**Supplementary Table S2.** Baseline characteristics of study population II (education as exposure) stratified by sex.

| | Men | | | Women | | |
|---|---|---|---|---|---|---|
| **Characteristics** | Low (n = 10,050) | Middle (n = 14,329) | High (n = 5,817) | Low (n = 7,079) | Middle (n = 4,874) | High (n = 2,292) |
| **Days of follow-up, median (25th-75th percentile)** | 1,020 (257-1,957) | 1,130 (397-2,046) | 1,167 (441-2,042) | 977 (178-1,880) | 1,150 (431-2,040) | 1,222 (518-2,034) |
| **Age (years), median + SD** | 65.3 (12.7) | 62.9 (11.7) | 63.6 (11.2) | 71.4 (12.3) | 65.7 (12.5) | 64.6 (12.2) |
| **Age group (years), n (%)** | | | | | | |
| < 65 years | 4,526 (45.0) | 7,817 (54.6) | 2,992 (51.4) | 1,894 (26.8) | 2,148 (44.1) | 1,138 (49.7) |
| 65-74 years | 2,854 (28.4) | 4,101 (28.6) | 1,825 (31.4) | 1,933 (27.3) | 1,436 (29.5) | 622 (27.1) |
| ≥ 75 years | 2,670 (26.6) | 2,411 (16.8) | 1,000 (17.2) | 3,252 (45.9) | 1,290 (26.5) | 532 (23.2) |
| **Ethnicity, n (%)** | | | | | | |
| Immigrants/Descendants | 777 (7.7) | 990 (6.9) | 610 (10.5) | 312 (4.4) | 264 (5.4) | 163 (7.1) |
| **Income level, n (%)** | | | | | | |
| Low | 4,190 | 3,539 | 660 | 4,163 (58.8) | 1,551 (31.8) | 318 (13.9) |
| Middle | 3,684 | 5,201 | 1,301 | 2,074 (29.3) | >1,873 (>38.3) | >745 (>32.5) |
| High | 2,155 | 5,551 | 3,844 | 833 (11.8) | 1,442 (29.6) | 1,225 (53.4) |
| Missing | 21 | 38 | 12 | 9 (0.1) | < 8 (<0.1) | <5(<0.2) |
| **Civil status, n (%)** | | | | | | |
| Single living | 3.227 (32.1) | 3,506 (24.5) | 1,132 (19.5) | 3,764 (53.2) | 1,984 (40.7) | 894 (39.0) |
| **Somatic comorbidity (CCI), n (%)** | | | | | | |
| None (0 points) | 586 (5.8) | 972 (6.8) | 469 (8.1) | 453 (6.4) | 413 (8.5) | 237 (10.3) |
| Moderate (1-2 points) | 7,667 (76.3) | 11,262 (78.6) | 4,663 (80.2) | 4,939 (69.8) | 3,625 (74.4) | 1,716 (74.9) |
| High (>2 points) | 1,797 (17.9) | 2,095 (14.6) | 685 (11.8) | 1,687 (23.8) | 836 (17.2) | 339 (14.8) |
| **Psychiatric comorbidity, n (%)** | | | | | | |
| Current (<90 days) | 1,199 (11.9) | 1,309 (9.1) | 527 (9.1) | 1,823 (25.8) | 1,004 (20.6) | 393 (17.1) |
| Recent (90-365 days) | 499 (5.0) | 686 (4.8) | 333 (5.7) | 632 (8.9) | 442 (9.1) | 168 (7.3) |
| Past (>365 days) | 1,850 (18.4) | 2,538 (17.7) | 983 (16.9) | 1,643 (23.2) | 1,156 (23.7) | 536 (23.4) |
| None | 6,502 (64.7) | 9,796 (68.4) | 3,974 (68.3) | 2,981 (42.1) | 2,272 (46.6) | 1,195 (52.1) |
| **Prior treatment, n (%)** | | | | | | |
| Antiplatelets | 3,465 (34.5) | 4,782 (33.4) | 1,848 (31.8) | 3,193 (45.1) | 1,811 (37.2) | 789 (34.4) |
| Statins | 3,236 (32.2) | 4,088 (28.5) | 1,572 (27.0) | 2,854 (40.3) | 1,560 (32.0) | 692 (30.2) |
| **Percutaneous coronary intervention, n (%)** | 4,515 (44.9) | 6,745 (47.1) | 2,768 (47.6) | 2,236 (31.6) | 1,735 (35.6) | 884 (38.6) |

**Supplementary Table S3:** Events, event rates (95% CI), and hazard ratios (95% CI) for the association between **income** and risk of non-persistence to medication and clinical events using none or 30-days window of initiation of medication

| | No criteria | | | 30 days | | |
|---|---|---|---|---|---|---|
| | Low (n = 20,167) | Middle (n = 20,167) | High (n = 20,167) | Low (n = 12,652) | Middle (n = 12,651) | High (n = 12,651) |
| **Major adverse cardiovascular event** | | | | | | |
| Unadjusted | | | | | | |
| Events | 10,952 | 8,412 | 5,858 | 6,010 | 4,371 | 3,332 |
| Event rate per 100,000 person-years | 55.4 (54.4-56.5) | 37.6 (36.8-38.4) | 23.4 (22.8-24.0) | 42.0 (41.0-43.1) | 27.6 (26.8-28.4) | 20.8 (20.1-21.5) |
| Total effect, HR | 1 (reference) | 0.71 (0.70-0.73) | 0.47 (0.46-0.48) | 1 (reference) | 0.68 (0.66-0.71) | 0.52 (0.50-0.54) |
| Model 1 | | | | | | |
| Events | 10,873 | 8,856 | 7,308 | 5,822 | 4,570 | 3,898 |
| Event rate per 100,000 person-years | 46.4 (45.1-47.6) | 38.4 (37.4-39.4) | 30.9 (29.8-32.0) | 36.1 (34.9-27.3) | 28.4 (27.4-29.3) | 25.0 (23.8-26.2) |
| Total effect, HR | 1 (reference) | 0.82 (0.80-0.85) | 0.66 (0.64-0.68) | 1 (reference) | 0.79 (0.76-0.82) | 0.68 (0.65-0.71) |
| Model 2 | | | | | | |
| Events | 9,935 | 8,768 | 9,700 | 5,298 | 4,578 | 5,215 |
| Event rate per 100,000 person-years | 41.1 (39.7-42.6) | 37.8 (36.8-38.8) | 40.4 (37.4-43.7) | 32.4 (31.0-33.9) | 28.4 (27.4-29.4) | 31.8 (28.2-36.1) |
| Total effect, HR | 1 (reference) | 0.89 (0.87-0.92) | 0.81 (0.78-0.85) | 1 (reference) | 0.86 (0.83-0.90) | 0.81 (0.76-0.84) |
| **Non-persistence to medication** | | | | | | |
| Unadjusted | | | | | | |
| Unadjusted | 6,627 | 6,338 | 6,213 | 4,985 | 4,423 | 4,053 |
| Events | 32.2 (31.5-33.0) | 27.7 (27.0-28.4) | 25.3 (24.6-25.9) | 34.0 (33.1-35.0) | 27.7 (26.8-28.5) | 25.6 (24.8-26.4) |
| Event rate per 100,000 person-years | 1 (reference) | 0.86 (0.83-0.89) | 0.78 (0.76-0.81) | 1 (reference) | 0.81 (0.78-0.85) | 0.74 (0.71-0.77) |
| Total effect, HR | | | | | | |
| Model 1 | 7,371 | 6,545 | 6,745 | 5,272 | 4,587 | 4,460 |
| Events | 30.8 (30.0-31.7) | 27.7 (27.1-28.4) | 29.0 (28.1-29.9) | 32.6 (31.6-33.7) | 28.2 (27.4-29.0) | 29.0 (27.9-30.2) |
| Event rate per 100,000 person-years | 1 (reference) | 0.90 (0.86-0.93) | 0.91 (0.88-0.95) | 1 (reference) | 0.87 (0.81-0.90) | 0.87 (0.83-0.91) |
| Total effect, HR | | | | | | |
| Model 2 | 7,319 | 6,526 | 7,063 | 5,179 | 4,603 | 4,935 |
| Events | 30.5 (29.3-31.7) | 27.7 (27.0-28.4) | 29.3 (27.7-31.1) | 32.3 (31.0-33.7) | 28.4 (27.5-29.3) | 30.1 (28.2-32.1) |
| Event rate per 100,000 person-years | 1 (reference) | 0.91 (0.87-0.95) | 0.91 (0.86-0.96) | 1 (reference) | 0.88 (0.84-0.93) | 0.88 (0.82-0.94) |
| **All-cause death** | | | | | | |
| Unadjusted | | | | | | |
| Events | 7,452 | 4,458 | 2,097 | 3,296 | 1,569 | 801 |
| Event rate per 100,000 person-years | 27.5 (26.8-28.1) | 15.3 (14.8-15.7) | 6.8 (6.5-7.1) | 16.7 (16.2-17.3) | 7.6 (7.3-8.0) | 4.0 (3.7-4.3) |
| Total effect, HR | 1 (reference) | 0.56 (0.54-0.57) | 0.25 (0.24-0.26) | 1 (reference) | 0.46 (0.43-0.48) | 0.24 (0.22-0.25) |
| Model 1 | | | | | | |
| Events | 6,774 | 4,817 | 3,473 | 2,828 | 1,724 | 1,272 |
| Event rate per 100,000 person-years | 21.4 (20.8-22.0) | 16.0 (15.5-16.5) | 11.6 (11.0-12.3) | 12.9 (12.5-13.5) | 8.2 (7.8-8.6) | 6.4 (5.9-7.0) |
| Total effect, HR | 1 (reference) | 0.75 (0.72-0.78) | 0.52 (0.50-0.55) | 1 (reference) | 0.66 (0.62-0.70) | 0.50 (0.45-0.54) |
| Model 2 | | | | | | |
| Events | 6,006 | 4,800 | 5,520 | 2,440 | 1,776 | 2,116 |
| Event rate per 100,000 person-years | 18.8 (18.2-19.4) | 15.9 (15.4-16.4) | 18.0 (15.9-20.5) | 11.2 (10.7-11.7) | 8.5 (8.1-8.9) | 10.1 (7.7-13.4) |
| Total effect, HR | 1 (reference) | 0.85 (0.81-0.88) | 0.72 (0.67-0.78) | 1 (reference) | 0.78 (0.72-0.83) | 0.67 (0.58-0.77) |
| **Cardiac death** | | | | | | |
| Unadjusted | | | | | | |
| Events | 1,766 | 1,109 | 501 | 705 | 375 | 164 |
| Event rate per 100,000 person-years | 6.5 (6.2-6.8) | 3.8 (3.6-4.0) | 1.6 (1.5-1.8) | 3.6 (3.3-3.8) | 1.8 (1.6-2.0) | 0.8 (0.7-1.0) |
| Total effect, HR | 1 (reference) | 0.58 (0.54-0.62) | 0.25 (0.23-0.28) | 1 (reference) | 0.51 (0.45-0.57) | 0.22 (0.19-0.26) |
| Model 1 | | | | | | |

| | | | | | | |
|---|---|---|---|---|---|---|
| Events | 1,608 | 1.217 | 810 | 600 | 410 | 253 |
| Event rate per 100,000 person-years | 5.1 (4.8-5.3) | 4.0 (3.8-4.3) | 2.7 (2.4-3.0) | 2.7 (2.5-3.0) | 2.0 (1.8-2.2) | 1.3 (1.1-1.5) |
| Total effect, HR | 1 (reference) | 0.79 (0.73-0.85) | 0.51 (0.46-0.57) | 1 (reference) | 0.72 (0.64-0.82) | 0.46 (0.37-0.55) |
| Model 2 | | | | | | |
| Events | 1,410 | 1,240 | 1,266 | 521 | 422 | 376 |
| Event rate per 100,000 person-years | 4.4 (4.2-4.7) | 4.1 (3.9-4.4) | 4.1 (3.3-5.2) | 2.4 (2.2-2.6) | 2.0 (1.8-2.2) | 1.8 (1.3-2.4) |
| Total effect, HR | 1 (reference) | 0.93 (0.85-1.01) | 0.71 (0.60-0.84) | 1 (reference) | 0.87 (0.75-1.00) | 0.58 (0.43-0.79) |
| **Cardiac readmission** | | | | | | |
| Unadjusted | | | | | | |
| Events | 7,099 | 6,031 | 4,721 | 4,537 | 3,619 | 2,933 |
| Event rate per 100,000 person-years | 35.9 (35.1-36.8) | 26.9 (26.3-27.6) | 18.9 (18.4-19.4) | 31.7 (30.8-32.7) | 22.9 (22.1-23.6) | 18.3 (17.7-19.0) |
| Total effect, HR | 1 (reference) | 0.81 (0.78-0.83) | 0.61 (0.59-0.63) | 1 (reference) | 0.76 (0.73-0.79) | 0.62 (0.59-0.64) |
| Model 1 | | | | | | |
| Events | 7,336 | 6,239 | 5,477 | 4,532 | 3,738 | 3,322 |
| Event rate per 100,000 person-years | 31.3 (30.3-23.3) | 27.0 (26.3-27.8) | 23.1 (22.2-24.1) | 28.1 (27.0-29.2) | 23.2 (22.4-24.1) | 21.3 (20.2-22.4) |
| Total effect, HR | 1 (reference) | 0.86 (0.84 (0.89) | 0.74 (0.72-0.77) | 1 (reference) | 0.83 (0.80-0.86) | 0.74 (0.71-0.78) |
| Model 2 | | | | | | |
| Events | 6,804 | 6,157 | 6,800 | 4,180 | 3,724 | 4,272 |
| Event rate per 100,000 person-years | 28.2 (27.0-29.3) | 26.5 (25.8-27.4) | 28.4 (26.0-31.0) | 25.6 (24.4-26.9) | 23.1 (22.2-24.0) | 26.1 (23.2-29.4) |
| Total effect, HR | 1 (reference) | 0.91 (0.88-0.94) | 0.86 (0.82-0.92) | 1 (reference) | 0.89 (0.85-0.93) | 0.87 (0.80-0.94) |

Model 1: Weighted by/ adjusted for age group, sex, ethnicity.
Model 2: Weighted by/ adjusted for age group, sex, ethnicity, civil status, somatic and psychiatric comorbidity.

**Supplementary Table S4.** Events, event rates (95% CI), and hazard ratios (95% CI) for the association between **education** and risk of non-persistence to medication and clinical events using none or 30-days window of initiation of medication

| | No criteria | | | 30 days | | |
|---|---|---|---|---|---|---|
| | Low (n = 23,451) | Middle (n = 24,201) | High (n = 10,389) | Low (n = 13,962) | Middle (n = 16,085) | High (n = 6,891) |
| **Major adverse cardiovascular event** | | | | | | |
| Unadjusted | | | | | | |
| Events | 12,102 | 9,559 | 3,561 | 6,109 | 5,501 | 2,103 |
| Event rate per 100,000 person-years | 48.7 (47.8-49.6) | 32.7 (32.0-33.3) | 27.3 (26.4-28.2) | 37.0 (36.1-37.9) | 26.6 (25.9-27.4) | 23.4 (22.5-24.5) |
| Total effect | 1 (reference) | 0.73 (0.72-0.75) | 0.63 (0.61-0.65) | 1 (reference) | 0.76 (0.73-0.78) | 0.67 (0.64-0.70) |
| Model 1 | | | | | | |
| Events | 11,210 | 10,078 | 3,796 | 5,702 | 5,748 | 2,185 |
| Event rate per 100,000 person-years | 42.4 (41.4-43.4) | 35.4 (34.6-36.3) | 30.1 (29.0-31.2) | 33.2 (32.2-34.2) | 28.3 (27.4-29.1) | 24.7 (23.6-25.9) |
| Total effect | 1 (reference) | 0.86 (0.84-0.88) | 0.75 (0.72-0.77) | 1 (reference) | 0.87 (0.84-0.90) | 0.77 (0.74-0.81) |
| Model 2 | | | | | | |
| Events | 10,571 | 10,215 | 4,161 | 5,392 | 5,808 | 2,381 |
| Event rate per 100,000 person-years | 39.8 (38.8-40.8) | 36.0 (35.2-36.9) | 31.8 (30.3-33.4) | 31.5 (30.4-32.5) | 28.7 (27.8-29.5) | 25.7 (24.2-27.3) |
| Total effect | 1 (reference) | 0.92 (0.90-0.94) | 0.88 (0.85-0.92) | 1 (reference) | 0.92 (0.89-0.95) | 0.88 (0.84-0.93) |
| **Non-persistence to medication** | | | | | | |
| Unadjusted | | | | | | |
| Events | 7,599 | 7,942 | 3,637 | 5,143 | 5,704 | 2,614 |
| Event rate per 100,000 person-years | 29.2 (28.5-29.9) | 26.9 (26.3-27.4) | 29.2 (28.3-30.2) | 30.0 (29.1-30.8) | 27.5 (26.8-28.2) | 30.4 (29.2-31.6) |
| Total effect | 1 (reference) | 0.93 (0.90-0.96) | 1.00 (0.96-1.04) | 1 (reference) | 0.92 (0.89-0.96) | 1.01 (0.96-1.06) |
| Model 1 | | | | | | |
| Events | 7,584 | 8,008 | 3,659 | 4,999 | 5,831 | 2,654 |
| Event rate per 100,000 person-years | 27.5 (26.8-28.1) | 27.8 (27.2-28.5) | 30.3 (29.3-31.3) | 28.1 (27.3-28.9) | 28.6 (27.8-29.4) | 31.4 (30.2-32.7) |
| Total effect, HR | 1 (reference) | 1.00 (0.98-1.04) | 1.09 (1.05-1.14) | 1 (reference) | 1.01 (0.97-1.05) | 1.11 (1.06-1.17) |
| Model 2 | | | | | | |
| Events | 7,486 | 8,036 | 3,821 | 4,871 | 5,855 | 2,823 |
| Event rate per 100,000 person-years | 27.1 (26.4-27.9) | 28.0 (27.4-28.7) | 30.4 (29.1-31.7) | 27.5 (26.6-28.4) | 28.8 (28.0-29.6) | 31.9 (30.4-33.6) |
| Total effect, HR | 1 (reference) | 1.03 (0.99-1.06) | 1.14 (1.09-1.20) | 1 (reference) | 1.04 (1.00-1.08) | 1.18 (1.12-1.25) |
| **All-cause death** | | | | | | |
| Unadjusted | | | | | | |
| Events | 7,60 | 4,711 | 1,636 | 3,051 | 1,934 | 681 |
| Event rate per 100,000 person-years | 23.0 (22.5-23.5) | 12.5 (12.1-12.9) | 10.0 (9.6-10.5) | 13.7 (13.2-14.2) | 7.2 (6.9-7.6) | 6.0 (5.6-6.5) |
| Total effect | 1 (reference) | 0.56 (0.54-0.58) | 0.45 (0.43-0.47) | 1 (reference) | 0.53 (0.50-0.56) | 0.44 (0.40-0.48) |
| Model 1 | | | | | | |
| Events | 6,526 | 5,318 | 1,881 | 2,560 | 2,184 | 766 |
| Event rate per 100,000 person-years | 18.6 (18.1-19.0) | 14.4 (14.0-14.9) | 11.8 (11.3-12.4) | 11.2 (10.8-11.6) | 8.3 (7.9-8.7) | 6.8 (6.3-7.3) |
| Total effect | 1 (reference) | 0.78 (0.75-0.81) | 0.64 (0.61-0.68) | 1 (reference) | 0.74 (0.70-0.78) | 0.62 (0.57-0.68) |
| Model 2 | | | | | | |
| Events | 5,925 | 5,479 | 2,110 | 2,301 | 2,252 | 847 |
| Event rate per 100,000 person-years | 17.0 (16.5-17.4) | 14.9 (14.5-15.4) | 12.6 (11.8-13.4) | 10.2 (9.8-10.6) | 8.5 (8.2-8.9) | 7.1 (6.4-7.8) |
| Total effect | 1 (reference) | 0.86 (0.83-0.89) | 0.82 (0.77-0.88) | 1 (reference) | 0.81 (0.76-0.86) | 0.74 (0.67-0.83) |
| **Cardiac death** | | | | | | |
| Unadjusted | | | | | | |
| Events | 1,900 | 1,094 | 382 | 684 | 406 | 154 |
| Event rate per 100,000 person-years | 5.7 (5.4-6.0) | 2.9 (2.7-3.1) | 2.3 (2.1-2.6) | 3.1 (2.9-3.3) | 1.5 (1.4-1.7) | 1.4 (1.2-1.6) |

| | | | | | | |
|---|---|---|---|---|---|---|
| Total effect | 1 (reference) | 0.54 (0.50-0.58) | 0.44 (0.39-0.49) | 1 (reference) | 0.50 (0.44-0.56) | 0.45 (0.38-0.53) |
| Model 1 | | | | | | |
| Events | 1,625 | 1,235 | 432 | 580 | 453 | 169 |
| Event rate per 100,000 person-years | 4.6 (4.4-4.9) | 3.4 (3.2-3.6) | 2.7 (2.5-3.0) | 2.5 (2.3-2.7) | 1.7 (1.6-1.9) | 1.5 (1.3-1.8) |
| Total effect | 1 (reference) | 0.73 (0.68-0.79) | 0.60 (0.54-0.67) | 1 (reference) | 0.67 (0.59-0.76) | 0.60 (0.50-0.71) |
| Model 2 | | | | | | |
| Events | 1,491 | 1,271 | 471 | 518 | 467 | 185 |
| Event rate per 100,000 person-years | 4.3 (4.1-4.5) | 3.5 (3.2-3.7) | 2.8 (2.5-3.2) | 2.3 (2.1-2.5) | 1.8 (1.6-2.0) | 1.5 (1.3-1.9) |
| Total effect | 1 (reference) | 0.80 (0.74-0.87) | 0.74 (0.65-0.85) | 1 (reference) | 0.75 (0.66-0.86) | 0.73 (0.58-0.91) |
| **Cardiac readmission** | | | | | | |
| Unadjusted | | | | | | |
| Events | 8,077 | 7,085 | 2,689 | 4,745 | 4,574 | 1,770 |
| Event rate per 100,000 person-years | 32.5 (31.8-33.2) | 24.2 (23.7-24.8) | 20.6 (19.9-21.4) | 28.7 (27.9-29.5) | 22.2 (21.5-22.8) | 19.7 (18.8-20.7) |
| Total effect | 1 (reference) | 0.83 (0.80-0.85) | 0.73 (0.70-0.76) | 1 (reference) | 0.82 (0.80-0.85) | 0.74 (0.71-0.78) |
| Model 1 | | | | | | |
| Events | 7,807 | 7,282 | 2,794 | 4,551 | 4,713 | 1,811 |
| Event rate per 100,000 person-years | 29.5 (28.7-30.3) | 25.6 (24.9-26.3) | 22.1 (21.2-23.1) | 26.5 (25.6-27.4) | 23.2 (22.4-24.0) | 20.5 (19.5-21.6) |
| Total effect | 1 (reference) | 0.94 (0.92-0.97) | 0.90 (0.86-0.94) | 1 (reference) | 0.94 (0.91-0.97) | 0.90 (0.86-0.95) |
| Model 2 | | | | | | |
| Events | 7,471 | 7,344 | 3,071 | 4,363 | 4,749 | 1,986 |
| Event rate per 100,000 person-years | 28.1 (27.3-29.0) | 25.9 (25.2-26.6) | 23.5 (22.2-24.8) | 25.4 (24.5-26.4) | 23.4 (22.7-24.2) | 21.4 (20.1-22.9) |
| Total effect | 1 (reference) | 0.94 (0.92-0.97) | 0.92 (0.88-0.97) | 1 (reference) | 0.94 (0.90-0.97) | 0.91 (0.86-0.97) |

Model 1: Weighted by/ adjusted for age group, sex, ethnicity.
Model 2: Weighted by/ adjusted for age group, sex, ethnicity, civil status, somatic and psychiatric comorbidity.